These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30458933)

  • 41. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration.
    Hogerzeil HV; Liberman J; Wirtz VJ; Kishore SP; Selvaraj S; Kiddell-Monroe R; Mwangi-Powell FN; von Schoen-Angerer T;
    Lancet; 2013 Feb; 381(9867):680-9. PubMed ID: 23410612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug Policy in Bulgaria.
    Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
    Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform.
    Wouters OJ; Kanavos PG
    Bull World Health Organ; 2015 Sep; 93(9):606-13. PubMed ID: 26478624
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Effects of Intellectual Property Rights on Access to Medicines and Catastrophic Expenditure.
    Jung Y; Kwon S
    Int J Health Serv; 2015; 45(3):507-29. PubMed ID: 26077858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Ensuring of safety of the circulation of medicines in the current demographic situation].
    Malichenko VS
    Adv Gerontol; 2014; 27(4):785-7. PubMed ID: 25946861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The consequences of 'Brexit' for drug discovery and development, and the regulatory implications.
    Golding BT; Waring MJ
    Expert Opin Drug Discov; 2018 Jul; 13(7):583-585. PubMed ID: 29634365
    [No Abstract]   [Full Text] [Related]  

  • 47. Assessment and improvement of the Italian healthcare system: first evidence from a pilot national performance evaluation system.
    Nuti S; Seghieri C; Vainieri M; Zett S
    J Healthc Manag; 2012; 57(3):182-98; discussion 198-9. PubMed ID: 22724376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Profile of access and use of medicines in the Brazilian population - contributions and challenges of PNAUM - Household Survey.
    Bermudez JA; Barros MB
    Rev Saude Publica; 2016 Dec; 50(suppl 2):2s. PubMed ID: 27982385
    [No Abstract]   [Full Text] [Related]  

  • 49. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The rise and fall of democratic universalism: health care reform in Italy, 1978-1994.
    Ferrera M
    J Health Polit Policy Law; 1995; 20(2):275-302. PubMed ID: 7636124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contemporary challenges on access to medicines: beyond the UNSG High-Level Panel.
    Bermudez J
    Cien Saude Colet; 2017 Aug; 22(8):2435-2439. PubMed ID: 28793061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Governing decentralization in health care under tough budget constraint: what can we learn from the Italian experience?
    Tediosi F; Gabriele S; Longo F
    Health Policy; 2009 May; 90(2-3):303-12. PubMed ID: 19058869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Judicialization of access to medicines in Minas Gerais state, Southeastern Brazil.
    Machado MA; Acurcio Fde A; Brandão CM; Faleiros DR; Guerra AA; Cherchiglia ML; Andrade EI
    Rev Saude Publica; 2011 Jun; 45(3):590-8. PubMed ID: 21445458
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Health Impact Fund: incentives for improving access to medicines.
    Banerjee A; Hollis A; Pogge T
    Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
    [No Abstract]   [Full Text] [Related]  

  • 55. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
    Thatte U; Hussain S; de Rosas-Valera M; Malik MA
    Value Health; 2009; 12 Suppl 3():S18-25. PubMed ID: 20586975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Innovative medicinal products: the new criteria of the Italian Medicines Agency.].
    Mammarella F; Tafuri G
    Recenti Prog Med; 2018 May; 109(5):261-262. PubMed ID: 29771247
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.
    Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
    Global Health; 2017 Aug; 13(1):53. PubMed ID: 28764738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stakeholders Perspectives on the Success Drivers in Ghana's National Health Insurance Scheme - Identifying Policy Translation Issues.
    Fusheini A; Marnoch G; Gray AM
    Int J Health Policy Manag; 2017 May; 6(5):273-283. PubMed ID: 28812815
    [TBL] [Abstract][Full Text] [Related]  

  • 59. National Survey on Access, Use and Promotion of Rational Use of Medicines (PNAUM): evaluation of pharmaceutical services in the primary health care.
    Akerman M; Freitas O
    Rev Saude Publica; 2017 Nov; 51(suppl 2):1s. PubMed ID: 29160468
    [No Abstract]   [Full Text] [Related]  

  • 60. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.